These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Mantegazza R; O'Brien FL; Yountz M; Howard JF; Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461 [TBL] [Abstract][Full Text] [Related]
11. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series. Datta S; Singh S; Govindarajan R J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555 [TBL] [Abstract][Full Text] [Related]
12. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F; Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717 [TBL] [Abstract][Full Text] [Related]
13. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF; Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K; J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177 [TBL] [Abstract][Full Text] [Related]
15. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF; Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455 [TBL] [Abstract][Full Text] [Related]
16. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Granit V; Benatar M; Kurtoglu M; Miljković MD; Chahin N; Sahagian G; Feinberg MH; Slansky A; Vu T; Jewell CM; Singer MS; Kalayoglu MV; Howard JF; Mozaffar T; Lancet Neurol; 2023 Jul; 22(7):578-590. PubMed ID: 37353278 [TBL] [Abstract][Full Text] [Related]
17. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF; Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021 [TBL] [Abstract][Full Text] [Related]
18. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M; Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T; Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]